Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BO 112

Drug Profile

BO 112

Alternative Names: BO-112; Nanoplexed Poly IC BO-112; Nanoplexed Polyinosinic:Polycytidylic Acid BO-112

Latest Information Update: 08 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bioncotech Therapeutics
  • Developer Highlight Therapeutics; Merck Sharp & Dohme; UCLAs Jonsson Comprehensive Cancer Center
  • Class Antineoplastics; Immunotherapies; RNA
  • Mechanism of Action DDX58 protein stimulants; IFIH1 protein stimulants; Immunostimulants; PMAIP1 protein stimulants; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Gastric cancer; Malignant melanoma
  • Phase I/II Non-small cell lung cancer
  • Phase I Liver cancer
  • No development reported Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 08 Feb 2024 Bioncotech Therapeutics completes a phase I trial in Solid tumours (Monotherapy, Combination therapy, Second-line therapy or greater) in Spain (Intratumoural) (NCT02828098)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Soft tissue sarcoma(Combination therapy) in USA (Intratumoural, Injection)
  • 13 Jun 2022 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Spain (Intratumoural) (NCT05265650)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top